Jonathan Meyer

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, USA
    J Clin Psychiatry 63:425-33. 2002
  2. ncbi request reprint Lithium toxicity after switch from fosinopril to lisinopril
    Jonathan M Meyer
    Department of Psychiatry, Veterans Affairs San Diego Healthcare System, University of California, San Diego, CA 92161, USA
    Int Clin Psychopharmacol 20:115-8. 2005
  3. pmc Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
    Jonathan M Meyer
    Department of Psychiatry, University of California at San Diego, USA
    Biol Psychiatry 66:1013-22. 2009
  4. pmc Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
    Schizophr Res 103:104-9. 2008
  5. ncbi request reprint The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome
    Jonathan M Meyer
    VA San Diego Healthcare System, USA
    Schizophr Res 80:9-18. 2005
  6. ncbi request reprint Antipsychotic safety and efficacy concerns
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, CA 92161, USA
    J Clin Psychiatry 68:20-6. 2007
  7. pmc Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, USA
    Schizophr Res 101:273-86. 2008
  8. ncbi request reprint Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego 92161, USA
    J Clin Psychiatry 68:28-33. 2007
  9. ncbi request reprint Prevalence of the metabolic syndrome in veterans with schizophrenia
    Jonathan Meyer
    Veterans Affairs San Diego Healthcare System and University of California, San Diego School of Medicine, USA
    J Psychiatr Pract 12:5-10. 2006
  10. ncbi request reprint Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study
    Jonathan M Meyer
    Veterans Administration San Diego Healthcare System, California 92161, USA
    Clin Ther 27:1930-41. 2005

Research Grants

Detail Information

Publications42

  1. ncbi request reprint A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, USA
    J Clin Psychiatry 63:425-33. 2002
    ..The goal of this retrospective study was to examine the changes in weight parameters, fasting glucose, and fasting lipids in long-term inpatients treated with either risperidone or olanzapine...
  2. ncbi request reprint Lithium toxicity after switch from fosinopril to lisinopril
    Jonathan M Meyer
    Department of Psychiatry, Veterans Affairs San Diego Healthcare System, University of California, San Diego, CA 92161, USA
    Int Clin Psychopharmacol 20:115-8. 2005
    ....
  3. pmc Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study
    Jonathan M Meyer
    Department of Psychiatry, University of California at San Diego, USA
    Biol Psychiatry 66:1013-22. 2009
    ..Despite the known CV effects of atypical antipsychotics, there is limited prospective data on IM changes during treatment...
  4. pmc Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, VA San Diego Healthcare System, San Diego, CA 92161, United States
    Schizophr Res 103:104-9. 2008
    ..Given concerns over antipsychotic effects on serum TG, this analysis explored changes in nonfasting TG in phase 1 of the CATIE Schizophrenia Trial...
  5. ncbi request reprint The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome
    Jonathan M Meyer
    VA San Diego Healthcare System, USA
    Schizophr Res 80:9-18. 2005
    ....
  6. ncbi request reprint Antipsychotic safety and efficacy concerns
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, CA 92161, USA
    J Clin Psychiatry 68:20-6. 2007
    ..Given the widespread use of atypical antipsychotics, the psychiatric community has come to recognize that monitoring of metabolic side effects is the new standard of care for treating severely mentally ill patients...
  7. pmc Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, USA
    Schizophr Res 101:273-86. 2008
    ..Given concerns over antipsychotic metabolic effects, this analysis explored MS status and outcomes in phase 1 of the CATIE Schizophrenia Trial...
  8. ncbi request reprint Strategies for the long-term treatment of schizophrenia: real-world lessons from the CATIE trial
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego 92161, USA
    J Clin Psychiatry 68:28-33. 2007
    ..Mental health providers in the United States are now studying models that support the integration of psychiatric and nonpsychiatric medical treatment to address the complexity of multimodal schizophrenia care...
  9. ncbi request reprint Prevalence of the metabolic syndrome in veterans with schizophrenia
    Jonathan Meyer
    Veterans Affairs San Diego Healthcare System and University of California, San Diego School of Medicine, USA
    J Psychiatr Pract 12:5-10. 2006
    ..S. veterans with schizophrenia...
  10. ncbi request reprint Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study
    Jonathan M Meyer
    Veterans Administration San Diego Healthcare System, California 92161, USA
    Clin Ther 27:1930-41. 2005
    ....
  11. doi request reprint The metabolic syndrome and schizophrenia
    J M Meyer
    Veterans Affairs San Diego Healthcare System, La Jolla, CA, USA
    Acta Psychiatr Scand 119:4-14. 2009
    ....
  12. ncbi request reprint Awareness of obesity and weight issues among chronically mentally ill inpatients: a pilot study
    Jonathan M Meyer
    University of California, San Diego and San Diego VAMC, 92161, USA
    Ann Clin Psychiatry 14:39-45. 2002
    ..These findings have significant implications for programmatic measures to control weight gain among chronic inpatients, and for use of atypicals that have a greater propensity to cause weight gain...
  13. ncbi request reprint Antipsychotics and metabolics in the post-CATIE era
    Jonathan M Meyer
    Department of Psychiatry, University of California, La Jolla, CA 92093, USA
    Curr Top Behav Neurosci 4:23-42. 2010
    ....
  14. ncbi request reprint Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital
    Jonathan M Meyer
    University of California, San Diego, USA
    J Clin Psychiatry 64:540-5. 2003
    ..S. psychiatric patients without mental retardation who are HCV-seropositive. To address this issue, a comprehensive screening program was commenced at Oregon State Hospital (Salem, Ore.) beginning in 1999...
  15. doi request reprint Lurasidone: a new drug in development for schizophrenia
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, CA 92161, USA
    Expert Opin Investig Drugs 18:1715-26. 2009
    ..Lurasidone is a novel psychotropic agent in development for the treatment of schizophrenia and bipolar disorder...
  16. ncbi request reprint Quetiapine-induced diabetes with metabolic acidosis
    Jonathan M Meyer
    Department of Psychiatry, Veterans Affairs San Diego Healthcare System, San Diego, California, USA
    Int Clin Psychopharmacol 19:169-71. 2004
    ..This case illustrates another mechanism for sexual adverse effects, and the need for routine inquiry into sexual dysfunction during atypical antipsychotic therapy...
  17. ncbi request reprint The effects of antipsychotic therapy on serum lipids: a comprehensive review
    Jonathan M Meyer
    University of California, San Diego VAMC MC 116A, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
    Schizophr Res 70:1-17. 2004
    ....
  18. ncbi request reprint The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia
    Jonathan M Meyer
    Department of Psychiatry, VA San Diego Healthcare System and University of California, San Diego, CA, USA
    J Clin Psychiatry 70:318-25. 2009
    ..Race is strongly associated with risk for metabolic dysfunction, but there is limited prospective data concerning the impact of race on antipsychotic metabolic outcomes among patients with schizophrenia...
  19. ncbi request reprint Treating the mind and body in schizophrenia: risks and prevention
    Jonathan M Meyer
    San Diego VA Medical Center, La Jolla, CA 92161, USA
    CNS Spectr 9:25-33. 2004
    ....
  20. ncbi request reprint Bone mineral density in male schizophrenia patients: a review
    Jonathan M Meyer
    Departments of Psychiatry, University of California, San Diego, USA
    Ann Clin Psychiatry 18:43-8. 2006
    ....
  21. pmc The association between weight change and symptom reduction in the CATIE schizophrenia trial
    Eric Hermes
    Department of Psychiatry, Yale School of Medicine, 300 George Street, Ste 901, New Haven, CT 06511, USA
    Schizophr Res 128:166-70. 2011
    ..Weight gain and changes in metabolic indicators associated with some antipsychotics may be related to symptom improvement and thus an unavoidable correlate of clinical benefit...
  22. doi request reprint Antipsychotic prescribing practices following withdrawal of concomitant carbamazepine
    Danielle K Strack
    Sharp Mesa Vista Hospital, San Diego, CA 92123, USA
    J Psychiatr Pract 15:442-8. 2009
    ....
  23. doi request reprint Use of clinical markers to identify metabolic syndrome in antipsychotic-treated patients
    Hua Jin
    Department of Psychiatry, University of California, San Diego, Veterans Affairs San Diego Healthcare System, 3350 La Jolla Village Drive MC 116A, San Diego, CA 92161, USA
    J Clin Psychiatry 71:1273-8. 2010
    ..However, there are relatively few data from antipsychotic-treated patients, especially on the association between these markers and the clinical MetS diagnosis...
  24. pmc Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine
    John W Newcomer
    Department of Psychiatry, and Center for Clinical Studies, Washington University School of Medicine, St Louis, MO 63110, USA
    Schizophr Res 106:300-7. 2008
    ..This post-hoc analysis assessed changes in these parameters during treatment with the atypical antipsychotics olanzapine or aripiprazole using pooled data from three randomized, long-term clinical studies in patients with schizophrenia...
  25. ncbi request reprint Is there a therapeutic window with some antidepressants for analgesic response?
    J Hampton Atkinson
    VA San Diego Healthcare System, 3350 La Jolla Village Drive, 116A, San Diego, CA 92161, USA
    Curr Pain Headache Rep 13:93-9. 2009
    ..This article reviews the strengths, limitations, and potential of therapeutic drug monitoring of antidepressants and anticonvulsants as analgesics for selected chronic pain syndromes...
  26. ncbi request reprint Valproic acid-associated hyperammonemic encephalopathy: a case report from the psychiatric setting
    Ryan J Kimmel
    Department of Psychiatry, University of California San Diego, La Jolla, California 92093 0603R, USA
    Int Clin Psychopharmacol 20:57-8. 2005
    ..This case illustrates the need to check ammonia levels in psychiatric patients who are taking valproic acid and who present with new neurological symptoms...
  27. ncbi request reprint A comprehensive review of behavioral interventions for weight management in schizophrenia
    Catherine Loh
    Mental Illness Research, Education, and Clinical Centers MIRECC, Veterans Affairs San Diego Healthcare System, San Diego, CA, USA
    Ann Clin Psychiatry 18:23-31. 2006
    ..This review seeks to assess the potential of behavioral therapy for the management of obesity in individuals diagnosed with schizophrenia through a comprehensive review of all available literature on this subject...
  28. pmc Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin
    Hua Jin
    Department of Psychiatry, University of California at San Diego, USA
    Schizophr Res 100:70-85. 2008
    ..The purpose of this review is to summarize recent data on changes in these hormones during atypical antipsychotic treatment...
  29. ncbi request reprint Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans
    Adrian W Dollarhide
    VA San Diego Healthcare System, San Diego, CA 92161, USA
    J Clin Gastroenterol 41:322-8. 2007
    ..The aim of this study was to evaluate the impact of common psychiatric disorders on treatment completion of antiviral therapy prescribed to a series of hepatitis C virus (HCV) positive US veterans...
  30. ncbi request reprint The metabolic syndrome and schizophrenia: a review
    Jonathan Meyer
    University of California San Diego, San Diego, CA, USA
    Int Rev Psychiatry 17:173-80. 2005
    ..This article describes and summarizes the information available on metabolic syndrome in the mental illness disease area and the proposed mechanisms for the increased prevalence of the metabolic syndrome in this population...
  31. ncbi request reprint Cardiovascular effects of antipsychotics
    James W Michelsen
    University of California, San Diego, Department of Medicine, CA, USA
    Expert Rev Neurother 7:829-39. 2007
    ....
  32. ncbi request reprint Atypical antipsychotics and glucose dysregulation: a systematic review
    Hua Jin
    Department of Psychiatry, University of California, San Diego VAMC, 3350 La Jolla Village Drive MC 116A, San Diego, CA 92161, USA
    Schizophr Res 71:195-212. 2004
    ..Rational patient monitoring guidelines are also elucidated, particularly for high-risk populations that need more intensive scrutiny during treatment of AAP...
  33. ncbi request reprint Sexual dysfunction in patients treated with atypical antipsychotics
    Jonathan M Meyer
    Department of Psychiatry, University of California, San Diego, San Diego VAMC, USA
    J Clin Psychiatry 69:e26. 2008
    ..To establish clinically useful standards for switching agents, more studies are needed that focus on gradual cross-titration methods to achieve therapeutic doses for patients...
  34. ncbi request reprint Drug-drug interactions with antipsychotics
    Jonathan Meyer
    University of California, San Diego, USA
    CNS Spectr 12:6-9. 2007
  35. ncbi request reprint Risperidone-induced retrograde ejaculation: case report and review of the literature
    Catherine Loh
    Mental Illness Research Education and Clinical Centers MIRECC, Veterans Affairs San Diego Healthcare System, San Diego, California, USA
    Int Clin Psychopharmacol 19:111-2. 2004
    ..This case illustrates another mechanism for sexual adverse effects, and the need for routine inquiry into sexual dysfunction during atypical antipsychotic therapy...
  36. ncbi request reprint Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases
    Hua Jin
    Department of Psychiatry, University of California at San Diego, USA
    Ann Clin Psychiatry 14:59-64. 2002
    ..Clinicians should be aware of the potential risks of new-onset DM and DKA in patients taking atypical antipsychotics, and utilize appropriate clinical and laboratory monitoring to prevent serious adverse events...
  37. ncbi request reprint Evidence-based psychiatry: outcomes and decisions
    Jonathan M Meyer
    South Med J 100:861-2. 2007
  38. ncbi request reprint A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
    Donald C Goff
    Massachusetts General Hospital, Harvard Medical School, Department of Psychiatry 25 Staniford Street, Boston, MA 02114, USA
    Schizophr Res 80:45-53. 2005
    ..The incidence of coronary heart disease (CHD) and the relative contribution of CHD to increased mortality in schizophrenia patients are not clear, despite recent concerns about metabolic complications of certain atypical antipsychotics...
  39. ncbi request reprint Decreased bone mineral density in male schizophrenia patients
    David Lehman
    Schizophr Res 76:131-3. 2005
  40. ncbi request reprint Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline
    Henry A Nasrallah
    University of Cincinnati, Cincinnati, OH 45267 0559, USA
    Schizophr Res 86:15-22. 2006
    ....
  41. ncbi request reprint Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III
    Joseph P McEvoy
    Department of Psychiatry and Behavioral Sciences, Duke University, Clinical Research, John Umstead Hospital, 1003 12th Street, Butner, NC 27509, USA
    Schizophr Res 80:19-32. 2005
    ..One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet limited data exist on its prevalence in US patients with schizophrenia...
  42. ncbi request reprint Atypical antipsychotic therapy and hyperlipidemia: a review
    Carol E Koro
    GlaxoSmithKline, Upper Providence, Pennsylvania, USA
    Essent Psychopharmacol 6:148-57. 2005
    ..Patients with persistent dyslipidemia should be referred for lipid-lowering therapy or switched to a less lipid-enhancing antipsychotic agent...

Research Grants3

  1. The Metabolic Syndrome in Patients with Schizophrenia
    Jonathan Meyer; Fiscal Year: 2007
    ..abstract_text> ..